Table 1.
Characteristics of the studies included in the meta-analysis.
| Publication author, year | Site | Statin, daily dose | Follow-up (weeks) | Sample size (case/control) | DHEA assessment method |
|---|---|---|---|---|---|
| Banaszewska, 2007 [15] | Poland | Simvastatin 20 mg | 12 weeks | 45/48 | Specific radioimmunoassays |
| Banaszewska, 2009 [19] | Poland | Simvastatin 20 mg | 12 weeks | 37/36 | Electrochemiluminescence assays |
| Kazerooni, 2010 [20] | Iran | Simvastatin 20 mg | 12 weeks | 42/42 | Radioimmunoassays |
| Banaszewska, 2011 [21] | Poland | Simvastatin 20 mg | 24 weeks | 44/47 | Electrochemiluminescence assays |
| Raja-Khan, 2011 [13] | US | Atorvastatin 40 mg | 6 weeks | 9/11 | Not given |
| Rashidi, 2011 [16] | Iran | Simvastatin 20 mg | 8 weeks | 32/39 | Chemiluminescence assays |
| Sathyapalan, 2012 [22] | UK | Atorvastatin 20 mg | 12weeks | 19/18 | Competitive immunoassay |
| Celik, 2012 [14] | Turkey | Rosuvastatin 10 mg | 12weeks | 18/20 | Enzyme-linked immunoassay (ELISA) |
| Puurunen, 2013 [23] | Finland | Atorvastatin 20 mg | 24 weeks | 15/13 | Chemiluminescence immunoassay |
| Seyam, 2018 [24] | Egypt | Simvastatin 20 mg | 24 weeks | 100/100 | Chemiluminescence |